If you do have government insurance, explore Lilly's Patient Assistance Program instead
Some patients may also experience modest weight loss, which is a recognised effect of GLP-1 receptor agonists
The SUSTAIN trials assessed final once-weekly doses of 1.0 mg only, or 0.5 mg and 1.0 mg, of subcutaneous semaglutide (1625)
All of these points point to a clear takeaway: GLP-1 patients benefit from early conversations and proactive skin strategies
This unique combination helps regulate appetite, control blood sugar levels, and accelerate fat loss more efficiently
But fatigue that becomes debilitating, that prevents you from working or exercising, that does not improve after two to three weeks at a given dose, suggests the dose may be too aggressive for your current tolerance level